Resources
Explore how healthcare organizations, researchers, and life sciences partners from our global community use TriNetX to turn real-world patient data into evidence that drives progress.
In the high-stakes world of clinical research, innovation doesn’t just happen in the lab; it must cross the clinical trial finish line of regulatory submission. Yet for many sponsors, sites, and researchers, patient recruitment—or the “last mile”—remains a costly bottleneck where recruitment can lag, site enrollment can underperform, and promising treatments never receive approval.
The “last mile” of clinical research represents the crucial phase where protocols are put into action, and patient engagement becomes a reality. It’s about transforming well-laid plans into meaningful outcomes by efficiently connecting researchers, sites, and participants.
The path to groundbreaking discoveries in clinical research starts with a single, vital element: trusted data.
Fresh from the dynamic and idea-rich environment of ISPOR 2025, the premier global conference on health economics and outcomes research (HEOR), one message emerged loud and clear: innovation is rapidly reshaping the HEOR landscape, yet foundational challenges remain that require renewed attention and action.
Clinical trials are being reinvented by real-world data (RWD). In 2025, data-driven strategies won’t just complement trial design—they’ll define it. From protocol optimization to accelerated site identification, data is the new compass guiding clinical innovation
The result? Higher costs, longer timelines, and compromised outcomes. The need to solve these critical challenges has never been more urgent.
With Robert F. Kennedy Jr. now at the helm of the Department of Health and Human Services (HHS), his recent speech to agency staff marked the beginning of what could be a seismic shift in U.S. healthcare policy. Among his key initiatives: launching investigations into whether antidepressants and the childhood vaccine schedule are contributing to chronic diseases.
Combining disparate data sources to inform clinical trial site selection has long been a complex challenge. Inconsistent site naming, differences in the definition of a site, and a lack of potential patient counts, among other obstacles, have made it difficult for sponsors to pinpoint optimal sites.
Real-world data (RWD) and the real-world evidence (RWE) derived from analysis of the data are a cornerstone of clinical advancements in today’s fast-paced research environment
The bispecific antibodies (bsAbs) teclistamab and talquetamab have received United States Food and Drug Administration (FDA) approval for use in relapsed/refractory multiple myeloma (MM) following remarkable single-agent activity in early-phase clinical trials.
The healthcare and clinical research industries are undergoing a seismic shift. Rapid advancements in real-world data (RWD), artificial intelligence (AI), and patient-centric approaches are rewriting the playbook for clinical trials and treatment development. The future of healthcare is here, and organizations that embrace these changes will be at the forefront of innovation.
Clinical trial site identification (ID) and outreach are often inefficient due to manual, paper-based processes, placing a heavy burden on both contract research organizations (CROs) and the clinical study sites with which they work.
Join a global community of innovators. Discover how to turn real-world data into groundbreaking clinical insights.
Meet TriNetX at Events
Bridge the gap between raw data and patient care. Meet the team at flagship healthcare conferences across the globe, and learn how to leverage the TriNetX ecosystem to streamline trial timelines, improve site collaboration, and publish research that changes lives.
